Biotech's IPO Tide Turning Amid M&A Surge on May 13, 2026 Alamar Biosciences IPOs Kailera Therapeutics M&A surge patent cliff +
GLP-1 Patent Cliffs and Biotech M&A Surge in 2026 on May 08, 2026 acquisitions generics Glucagon-Like Peptide 1 M&A patent cliff Pharma semaglutide +
Merck & Co.'s Keytruda Posts $8B in Q1 2026 as Qlex Picks Up Steam on May 01, 2026 Antineoplastic Agents earnings Keytruda Merck patent cliff pharmaceutical sales Qlex Subcutaneous Injections +
Patent Expirations Drive Biopharma Toward a Tougher 2026 with Major Revenue Risks on March 13, 2026 2026 Biosimilars blockbuster drugs Eliquis expirations generics Januvia Ozempic patent cliff pharma revenue +
J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff on January 23, 2026 2026 Darzalex J&J Johnson & Johnson medtech Neoplasms patent cliff Sales - occupational activity Shockwave Medical Stelara +
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff on January 13, 2026 JPM26 Metsera Obesity Drugs patent cliff Pfizer Phase 3 Clinical Trials +
Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites on December 17, 2025 2025 acquisition acquisitions fibroblast growth factor 21 Health care facility Johnson & Johnson Intra-Cellular M&A MASH Merck Verona patent cliff Pharma pharma patent expirations Sanofi Blueprint Medicines +
A closer look at pharmas top patent losses in 2025 on March 23, 2025 2023 2025 Bayer competition Expiration function Impact food supplement Indication of (contextual qualifier) Legal patent Market patent cliff Regeneron Sales - occupational activity +
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff on February 27, 2025 Impact food supplement IRA Keytruda Merck patent cliff Prices Sales - occupational activity U.S. +